Statements (56)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:awards |
biotechnology innovation awards
|
gptkbp:business_model |
research and development
commercialization of therapies |
gptkbp:can_lead_to |
KTX-001
|
gptkbp:clinical_trial |
gptkb:Company
ongoing Phase 1 Phase 2 multicenter studies positive results overall survival progression-free survival |
gptkbp:collaborations |
academic institutions
industry partners |
gptkbp:committee |
experts in immunology
|
gptkbp:community_engagement |
patient advocacy groups
|
gptkbp:focus |
gptkb:drug
|
gptkbp:founded |
gptkb:2015
|
gptkbp:founder |
Dr. R. Scott Mc Iver
|
gptkbp:future_plans |
develop new therapies
increase funding opportunities expand clinical trials enhance patient access |
gptkbp:headquarters |
gptkb:Houston,_Texas
|
https://www.w3.org/2000/01/rdf-schema#label |
Kuur Therapeutics
|
gptkbp:invention |
granted patents
|
gptkbp:investment |
gptkb:Europe
gptkb:North_America Venture capital firms |
gptkbp:language_of_instruction |
multiple product candidates
|
gptkbp:leadership |
experienced management team
|
gptkbp:mission |
develop innovative therapies
|
gptkbp:partnership |
gptkb:MD_Anderson_Cancer_Center
|
gptkbp:partnerships |
biopharma collaborations
|
gptkbp:platform |
gptkb:drug
|
gptkbp:population |
diverse demographics
|
gptkbp:publishes |
peer-reviewed journals
|
gptkbp:receives_funding_from |
Series A funding
Series B funding |
gptkbp:regulatory_compliance |
gptkb:FDA
IND applications |
gptkbp:research_areas |
oncology
personalized medicine hematology |
gptkbp:research_focus |
immune modulation
|
gptkbp:safety_features |
monitored closely
|
gptkbp:strategic_importance |
expand product pipeline
increase market presence enhance clinical development |
gptkbp:targets |
gptkb:healthcare_organization
autoimmune disorders |
gptkbp:technology |
gptkb:drug
|
gptkbp:website |
www.kuurtherapeutics.com
|
gptkbp:bfsParent |
gptkb:Athenex
|
gptkbp:bfsLayer |
3
|